Show simple item record

dc.contributor.authorKhan, Sohilen_US
dc.contributor.authorHeussler, Helenen_US
dc.contributor.authorMcGuire, Treasureen_US
dc.contributor.authorDakin, Carolynen_US
dc.contributor.authorPache, Daviden_US
dc.contributor.authorCooper, Daviden_US
dc.contributor.authorNorris, Rossen_US
dc.contributor.authorFlenady, Vickien_US
dc.contributor.authorCharles, Bruceen_US
dc.date.accessioned2017-11-16T12:00:34Z
dc.date.available2017-11-16T12:00:34Z
dc.date.issued2011en_US
dc.date.modified2012-05-15T22:49:12Z
dc.identifier.issn1469-493Xen_US
dc.identifier.doi10.1002/14651858.CD008473.pub2en_US
dc.identifier.urihttp://hdl.handle.net/10072/43687
dc.description.abstractBackground Exogenous melatonin helps in regulating the circadian rhythm and is widely used for the management of sleep disorders in visually impaired children. Objectives The aim of the review was to assess melatonin therapy for treatment of non-respiratory sleep disorders in visually impaired children, with regard to improvement in sleep habit, sleep scheduling and sleep maintenance, when compared with placebo or no treatment. Search strategy We searched the following databases between February 2011 and July 2011: the Cochrane Central Register of Controlled Trials (CENTRAL) 2011(1) searched on 4th February 2011;MEDLINE (1950 to JuneWeek 3, 2011) searched on 20th June 2011; EMBASE (1980 to June Week 4, 2011) searched on 7th July 2011; CINAHL (1937 to 21 September 2011); the metaRegister of Controlled Trials (this includes ClinicalTrial.gov) searched 20 July 2011, and reference lists of papers identified after initial screening. Selection criteria We planned to include randomized controlled trials (RCTs) and quasi-RCTs, including cross-over studies.Treatmentwould be exogenous melatonin. Control groups could be placebo, other medication for sleep disorders or no treatment. Outcomes sought were improved sleep with regard to timing and duration, quality of life and adverse events. Data collection and analysis Three review authors independently assessed trials for inclusion in the review. Main results We did not find any studies fulfilling the inclusion criteria, therefore no outcome data are reported. We identified nine studies after initial screening and, after further evaluation, we excluded these. The excluded studies involved a total of 163 individuals aged two years to 18 years. We excluded studies for three main reasons: they were non-randomized or case series studies, they were studies of people over 18 years of age or even where the study was randomised, the study population was mixed and results pertaining to the visually impaired cohort could not be independently evaluated. No significant adverse effects of melatonin were reported in these excluded studies. Authors' conclusions There is currently no high quality data to support or refute the use of melatonin for sleep disorders in visually impaired children. Placebo-controlled trials examining important clinical outcomes such as sleep quality, sleep latency, duration of sleep and night-time awakenings are needed. As the numbers of children meeting study inclusion criteria are likely to be low at individual sites, multicentre collaboration between developmental paediatricians, sleep physicians and other health care professionals is essential to achieve sufficient sample size for controlled studies. Such collaboration would help facilitate local recruitment atmultiple sites, with study oversight being provided by paediatricians with expertise in sleep disorders. Participation of collaborators with experience in evidence-based practice research is also desirable due to the lack of protocols on melatonin therapy in the target population.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.format.extent239976 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherJohn Wiley & Sonsen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefromCD008473-1en_US
dc.relation.ispartofpagetoCD008473-21en_US
dc.relation.ispartofjournalThe Cochrane Database of Systematic Reviewsen_US
dc.relation.ispartofvolume11en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchClinical Pharmacology and Therapeuticsen_US
dc.subject.fieldofresearchcode111502en_US
dc.titleMelatonin for non-respiratory sleep disorders in visually impaired children (Review)en_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyright© 2011 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2011, Issue 11. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.en_US
gro.date.issued2011
gro.hasfulltextFull Text
gro.griffith.authorKhan, Sohil A.
gro.griffith.authorNorris, Ross LG.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record